China SXT Pharmaceuticals Inc
NASDAQ:SXTC
China SXT Pharmaceuticals Inc
NASDAQ:SXTC
Price:
2.42
USD
7.56%
Market Closed
Market Cap:
$2.3m
Relative Value
The Relative Value of one
SXTC
stock under the Base Case scenario is
6.4
USD.
Compared to the current market price of 2.42 USD,
China SXT Pharmaceuticals Inc
is
Undervalued by 62%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
SXTC
Relative Value
Base Case
6.4
USD
Undervaluation 62%
Multiples Across Competitors
SXTC Competitors Multiples
China SXT Pharmaceuticals Inc Competitors
China SXT Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
China SXT Pharmaceuticals Inc
NASDAQ:SXTC
|
2.3m USD | 1.5 | -0.3 | 2.1 | 2.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
987.9B USD | 15.2 | 47.9 | 32.3 | 34.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
596.5B USD | 6.3 | 22.3 | 15.4 | 19 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
293B CHF | 4.8 | 31.2 | 13.1 | 15.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
249.7B CHF | 5.7 | 23 | 14.2 | 18.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
240.5B GBP | 5.5 | 31.7 | 17.5 | 24.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
307.4B USD | 4.7 | 16.8 | 10.5 | 12.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.4 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.9B USD | 2.5 | 20.2 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD | 2.6 | 17.8 | 7.4 | 9.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
